CSL's (ASX:CSL) fiscal first-half adjusted net profit after tax (NPAT) of $2.07 billion fell 4% below estimates by Visible Alpha of $2.16 billion, The Australian reported Tuesday, citing investment bank Barrenjoey.
The company's full fiscal year adjusted NPAT guidance of $3.11 billion to $3.21 billion, including a $90 million "headwind," is 3% below Visible Alpha's estimates of $3.26 billion, per the report.
Barrenjoey noted that CSL's Vifor and Behring divisions reported revenue 4% and 1% above estimates, respectively.
However, its Seqirus division's revenue fell 15% below market estimates due to declining vaccination rates, changing immunization settings, and increased competitive pressures, the investment firm added.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.